Chiche(E),Fileni(C),Bonnet(S),Bertoli(S),K... Acta Haematol 2026-06-15

...ELN risk categories were favorable, intermediate and adverse in 3 (2%), 17 (13%), and 110 (85%), respectively. Overall r...

Ferrari(C),Coulleray(B),Kerneves(P),Geara(... Int J Lab Hematol 2026-06-15

...ELN guidelines and the growing need for personalized molecular monitoring in AML.

Kaur(G),Serwaa-Bonsu(A),Miyasako(K),McCorm... bioRxiv 2026-06-16

...Eln haploinsufficiency. Adult male and female Eln +/+ and Eln +/- mice were subjected to acute extracellular fluid volum...

Sato(N),Yoshimaru(R),Guo(YM),Nakamura(H),M... Case Rep Hematol None

...ELN guidelines, in the view of the clinical context of a second TFR attempt following prior failure. Imatinib was reintr...

Cheng(C),Bao(XJ),Liu(JB),Zheng(L),Wei(LT),... Asian J Androl 2026-06-30

...ELN], collagen type VI alpha 3 chain [COL6A3], collagen type V alpha 2 chain [COL5A2], and secreted protein acidic and r...

Joshi(U),Zahra(FT),Patel(P),Al Ali(N),Thom... Ann Hematol 2026-07-02

...ELN 2022 risk groups and most driver mutations were similarly distributed, Black patients exhibited a higher frequency o...

Hoff(FW),Zeidner(JF),Torlapati(G),Nicolet(... Am J Hematol 2026-09-00

...ELN) 2024 risk-classification for patients treated with hypomethylating agents plus venetoclax (HMA + VEN), NPM1 mut is ...

Madhulika(S),Panda(TS),Samal(P),Kumar(SS),... J Biol Chem 2026-07-00

...ELN-2017 classification, and significantly poorer survival. Classification of AML patients into HELLSHigh and HELLSLow g...

Elhassadi(E),O'Rourke(E),Bannaga(A),Kumar(... Ann Hematol 2026-05-30

...ELN 2022/2024 molecular classifications were applied. Survival analyses were performed using Prism v10.06, with statisti...

Ji(X),Ahmad(MF),Mokhtar(MH),He(X),Abdul Ka... Front Endocrinol (Lausanne) None

...ELN) recommendations.